Clinical trials: Residual Disease
Renal Cell Carcinoma (RCC)
Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma
This is a prospective cohort study aimed at clarifying the predictive value of MRD for postoperative DFS and OS in high-risk recurrent renal cell carcinoma patients who have undergone radical nephrectomy and received adjuvant…
- Trial name
- NCT07657325
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Tianjin Medical University Second Hospital
HCC, Minimal Residual Disease
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
Hepatocellular carcinoma (HCC) is a leading global cause of cancer-related mortality. While curative resection is pivotal, high postoperative recurrence rates remain a major challenge.
- Conditions
- HCC, Minimal Residual Disease, Recurrence
- Trial name
- NCT07350824
- Testing
- Adjuvant PD-1 inhibitors, Active monitoring
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Tongji Hospital
Leukemia
Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia
RATIONALE: Diagnostic procedures that detect residual disease may predict disease relapse in patients who have hairy cell leukemia.
- Trial name
- NCT00005619
- Testing
- polymerase chain reaction, flow cytometry, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Northwestern University
Opioid Use Disorder
Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
The goal of this pilot study is to test novel, adjunctive pharmacotherapy for patients with opioid use disorder (POUD) who may be at risk for overdose and other poor opioid use disorder (OUD) outcomes even after initiating…
- Trial name
- DEMURE (NCT07148206)
- Testing
- Dronabinol Capsules, Epidiolex 100 mg/mL Oral Solution
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Montefiore Medical Center
Leukemia, Myeloid, Chronic-Phase
Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response
The Imatinib Mesylate at a dose of 400 mg / day is the standard treatment for patients with CML-CP. Recent studies show that the quality of response rate (complete cytogenetic response and major molecular response rate) is…
- Trial name
- MIM (NCT01827930)
- Testing
- Imatinib Mesylate 600 MG Oral Tablet, Imatinib Mesylate 400 MG Oral Tablet, Imatinib Mesylate
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Institut Bergonié
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation
TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
The purpose of this study is to evaluate the efficacy of tyrosine kinase inhibitor(TKI) therapy based on molecular monitoring of BCR/ABL levels in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)undergoing…
- Conditions
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation, Minimal Residual Disease
- Trial name
- NCT01883219
- Testing
- TKIs
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Multiple Myeloma, Minimal Residual Disease
Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry
Multiple myeloma (MM) is a severe plasma cell cancer caused by proliferation and accumulation of malignant plasma cells in the bone marrow. Novel therapies have improved responses and survival considerably.
- Trial name
- NCT07691034
- Testing
- Mass spectrometry
- Volunteers
- 40 people
- Sponsor
- Odense University Hospital
Breast Cancer Triple Negative
Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC
The main purpose of this study is to determine how 2 doses mirvetuximab soravtansine affects the amount and activity of folate receptor alpha proteins in tumor cells of patients who have completed standard neoadjuvant treatment…
- Trial name
- IMGN853 (NCT03045393)
- Testing
- Mirvetuximab Soravtansine (IMGN853)
- Where
- United States
- Sponsor
- Duke University
Resectable Colorectal Carcinoma, Stage II Colorectal Cancer AJCC v8
Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
This clinical trial compares minimal residual disease (MRD) testing with the Haystack blood test (assay) to the Signatera® assay for the early detection of the cancer returning (cancer recurrence) in patients with stage II-IV…
- Conditions
- Resectable Colorectal Carcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT07125729
- Testing
- Biospecimen Collection, cfDNA or ctDNA Measurement, Electronic Health Record Review
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- City of Hope Medical Center
Myocardial Infarction
Utility of Residual Syntax Score to Predict Outcome After Acute Myocardial Infarction
The aim of this study is to evaluate the utility of residual syntax score after PCI of the culprit vessel for patients with AMI (STEMI or NSTEMI) to predict 6-months clinical outcomes.
- Trial name
- NCT05392777
- Testing
- Residual syntax score
- Where
- Egypt
- Volunteers
- 490 people
- Sponsor
- Cairo University
Multiple Myeloma
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple myeloma is characterized by a pattern of recurrent relapse and remains an incurable malignancy. Participants with minimal residual disease (MRD) after front line therapy with induction and transplant have worse prognosis…
- Trial name
- ROTATE (NCT06993675)
- Testing
- Talquetamab, Teclistamab
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Noffar Bar
Acute Myeloid Leukemia
Study of GDX012 in Patients With MRD Positive AML
The purpose of this first-in-human study is to assess the safety, tolerability, antileukemic activity and maximum tolerated dose (MTD) of GDX012 in AML patients who are MRD positive by multiparametric flow cytometry.
- Trial name
- NCT05001451
- Testing
- GDX012 Suspension for IV Infusion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- GammaDelta Therapeutics Limited
Kidney Calculi
Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis
Extracorporeal shock wave lithotripsy (ESWL) and Percutaneous nephrolithotomy (PCNL) become the therapy of choice for renal stone.
- Trial name
- NCT01329042
- Testing
- Potassium-sodium citrate
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Ouiheng International Healthcare Co., Ltd
Child-Pugh Class A, Child-Pugh Class B
Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
This randomized phase III trial studies how well transarterial chemoembolization (TACE) works compared to stereotactic body radiation therapy (SBRT) or stereotactic ablative radiation therapy (SABR) in patients with liver cancer…
- Conditions
- Child-Pugh Class A, Child-Pugh Class B, Recurrent Hepatocellular Carcinoma
- Trial name
- NCT02762266
- Testing
- Stereotactic Body Radiation Therapy, Transarterial Chemoembolization, embolic agent
- Where
- 2 sites in United States, Japan
- Volunteers
- 13 people
- Sponsor
- Stanford University
Pulmonary Embolism, Venous Thromboembolism
Residual Pulmonary Vascular Obstruction Index Computed With Ventilation/Perfusion SPECT/CT Imaging to Predict the Risk of Venous Thromboembolism Recurrence in Patients With Pulmonary Embolism (PRONOSPECT)
Major risk after pulmonary embolism (PE) is recurrence, fatal in 10% of patients. Patients with PE can be stratified in 3 groups according to the risk of recurrence : very low risk, high risk or Intermediate risk.
- Trial name
- PRONOSPECT (NCT06372730)
- Testing
- Ventilation/Perfusion Single Photon Emission Computed Tomography (V/Q SPECT/CT)
- Where
- 13 sites in France
- Volunteers
- 665 people
- Sponsor
- University Hospital, Brest
Leukemia, Lymphocytic, Chronic, B-Cell
Phase II Trial GA101 Inbrutinib B CLL
Phase II study testing chemo-free induction therapy with Ibrutinib + Obinutuzumab nine months / Study Part 1: All patients will receive 8 courses of GA101 + ibrutinib 420mg PO every 28 days Study Part 2: After evaluation at D1 of…
- Trial name
- ICLL07GAI (NCT02666898)
- Testing
- GA101, Ibrutinib, Cyclophosphamide
- Where
- France
- Volunteers
- 135 people
- Sponsor
- French Innovative Leukemia Organisation
Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma
Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer
This prospective observational study evaluates a blood-based circulating tumor DNA (ctDNA) test in patients with muscle-invasive bladder cancer or upper tract urothelial cancer.
- Conditions
- Muscle-Invasive Bladder Cancer (MIBC), Upper Tract Urothelial Carcinoma, Urothelial Carcinoma (UC)
- Trial name
- BLUT-DNA (NCT07756437)
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- AZ Sint-Lucas Gent
Endometrial Cancer
Circulating Tumor DNA Study in Patients With Endometrial Cancer
The objective of this study is to identify a population at risk of early recurrence after oncologic resection surgery of a primary uterine tumor based on the detection of ctDNA
- Trial name
- ctDNA-endo (NCT05955079)
- Testing
- Whole blood
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Developmental Dislocation of the Hip, Congenital Dislocation of Hip
A Trial on the Opportunity and Treatment of Residual Deformity After Reduction in Developmental Dislocation of the Hip
Developmental dislocation of the hip is a common disease in children, and its incidence in China is about 9 ‰.The pathological changes of it is complex.
- Conditions
- Developmental Dislocation of the Hip, Congenital Dislocation of Hip, Residual Deformity, Reduction
- Trial name
- NCT02163603
- Testing
- Pelvic osteotomy
- Volunteers
- 2 people
- Sponsor
- Hongwen Xu
Pancreatitis, Chronic
Evaluation of the SpyGlass DS for Detection of Residual Pancreatic Calculations
The purpose of the study is to assess the efficacy of the SpyGlass DS for the detection of residual pancreatic calculations after endoscopic treatment.
- Trial name
- NCT04672642
- Testing
- SpyGlass DS
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Hospital St. Joseph, Marseille, France
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.